The Autoimmune Association is proud to announce a new partnership with U.S. Olympic swimmer Paige Madden, a decorated athlete and champion in the pool, to amplify awareness of autoimmune diseases.
UC San Diego researchers discover two distinct molecular subtypes of Crohn’s disease using patient-derived organoids, opening the door to personalized treatment for the chronic inflammatory bowel disease.
PARAGON Study Shows NEUROMARK® Treatment Benefits Allergic and Nonallergic Rhinitis Patients
A phase 2 trial of a monoclonal antibody known as tulisokibart for moderate-to-severe ulcerative colitis (UC) showed promising results for those who have not responded to conventional inflammatory bowel disease (IBD) treatment. The results were reported Thursday, September 26, in The New England Journal of Medicine.
Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an engineered immune cell therapy can halt the progression of the autoimmune disease.
Starting patients with multiple sclerosis (MS) on aggressive treatment earlier may help prevent the development of paramagnetic rim lesions (PRL), areas of chronic brain inflammation that are linked to faster decline due to the disease, suggests new research presented at the 149th Annual Meeting of the American Neurological Association (ANA). People with MS who have PRLs tend to have greater brain atrophy and disability. Treatment for MS includes low-, moderate- or high-efficacy disease-modifying therapies (DMTs), such as monoclonal antibodies, immunomodulators and immunosuppressants. While high-efficacy DMTs have more side effects, previous research suggests they may help prevent PRLs from forming (unlike low- or moderate-efficacy DMTs), potentially outweighing the downsides. No currently available DMT has been shown to reduce existing PRLs.
La Jolla Institute for Immunology (LJI) has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).
Scleroderma is a chronic autoimmune disease of women.Over time, people living with scleroderma develop progressive and irreversible scarring.Scarring, called fibrosis, effects the lungs, heart and kidneys, leading to poor quality of life, disability and a reduced life expectancy.
A computer model developed by UT Southwestern Medical Center researchers significantly enhances the ability of scientists to detect communication between cells, according to a new study published in Nature Methods.
EVOQ Therapeutics, Inc. (EVOQ) a biopharmaceutical company dedicated to the treatment of autoimmune diseases, announced today the receipt of a $2 million grant from the National Institutes of Health (NIH) to advance novel therapies for autoimmune diseases.
n a new study, a team of researchers from Columbia Engineering, Columbia University Vagelos College of Physicians and Surgeons, and Harvard University report that autoantibodies alone directly affect heart function in lupus patients.
New research from Memorial Sloan Kettering Cancer Center (MSK) found patients with non-small cell lung cancer brain metastases may benefit from up-front stereotactic radiosurgery; identified a connection between antibiotic use and autoimmune diseases; and uncovered a previously unknown structural role for messenger RNAs in the cytoplasm of cells.
Neutrophils are an important type of white blood cell that help your immune system fight infections. One of the many ways neutrophils help is by capturing germs in sticky, spider web-like structures called neutrophil extracellular traps, or NETs.However, excessive formation of NETs is seen in many autoimmune diseases as a sign of exuberant inflammation.
An interdisciplinary team of medical and engineering researchers has spent the last six years working to unlock a significant piece of the puzzle in the search for a cure: how and where the gluten response begins.
Thermo Fisher Scientific Inc. will showcase its broad diagnostics portfolio and host a series of customer-led workshops and presentations that highlight industry developments and the company’s latest innovations during the Association for Diagnostics & Laboratory Medicine Conference (ADLM) July 28-Aug. 1, 2024, in Chicago, Ill.
How a person’s immune system responds to a protein called LL-37 may increase risk for developing acute coronary syndrome, but the response may also serve as a potential target for future treatments.
Engineers at the University of California San Diego have developed a pill that releases microscopic robots, or microrobots, into the colon to treat inflammatory bowel disease (IBD). The experimental treatment, given orally, has shown success in mice.
The researchers hope to one day target this T cell population via drug therapy. "These cells may be a very important target for treating ulcerative colitis and perhaps other autoimmune diseases..."
Researchers at The University of Texas at El Paso are developing a new therapeutic approach that uses nanoparticles for the treatment of skin and lung fibrosis, conditions that can result in severe damage to the body’s tissues.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right